173 related articles for article (PubMed ID: 38554200)
1. DR30318, a novel tri-specific T cell engager for Claudin 18.2 positive cancers immunotherapy.
Ma Z; Zhou Z; Duan W; Yao G; Sheng S; Zong S; Zhang X; Li C; Liu Y; Ou F; Dahar MR; Huang Y; Yu L
Cancer Immunol Immunother; 2024 Mar; 73(5):82. PubMed ID: 38554200
[TBL] [Abstract][Full Text] [Related]
2. Preclinical characterization of a Fab-like CD3/CLDN18.2 XFab® bispecific antibody against solid tumors.
Xu G; Qian N; Liu Y; Li H; Yang C; Wang J; Wang F; Chen L; Bai G; Xu Q; Pan X; Gao X
Immunobiology; 2022 Nov; 227(6):152283. PubMed ID: 36198215
[TBL] [Abstract][Full Text] [Related]
3. Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer.
Zhu G; Foletti D; Liu X; Ding S; Melton Witt J; Hasa-Moreno A; Rickert M; Holz C; Aschenbrenner L; Yang AH; Kraynov E; Evering W; Obert L; Lee C; Sai T; Mistry T; Lindquist KC; Van Blarcom T; Strop P; Chaparro-Riggers J; Liu SH
Sci Rep; 2019 Jun; 9(1):8420. PubMed ID: 31182754
[TBL] [Abstract][Full Text] [Related]
4. Development of a Humanized VHH Based Recombinant Antibody Targeting Claudin 18.2 Positive Cancers.
Zhong W; Lu Y; Ma Z; He Y; Ding Y; Yao G; Zhou Z; Dong J; Fang Y; Jiang W; Wang W; Huang Y
Front Immunol; 2022; 13():885424. PubMed ID: 35837391
[TBL] [Abstract][Full Text] [Related]
5. CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation.
Gao J; Wang Z; Jiang W; Zhang Y; Meng Z; Niu Y; Sheng Z; Chen C; Liu X; Chen X; Liu C; Jia K; Zhang C; Liao H; Jung J; Sung E; Chung H; Zhang JZ; Zhu AX; Shen L
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37364935
[TBL] [Abstract][Full Text] [Related]
6. IL-15 armoring enhances the antitumor efficacy of claudin 18.2-targeting CAR-T cells in syngeneic mouse tumor models.
Shi H; Li A; Dai Z; Xue J; Zhao Q; Tian J; Song D; Wang H; Chen J; Zhang X; Zhou K; Wei H; Qin S
Front Immunol; 2023; 14():1165404. PubMed ID: 37564658
[TBL] [Abstract][Full Text] [Related]
7. Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer.
Jiang H; Shi Z; Wang P; Wang C; Yang L; Du G; Zhang H; Shi B; Jia J; Li Q; Wang H; Li Z
J Natl Cancer Inst; 2019 Apr; 111(4):409-418. PubMed ID: 30203099
[TBL] [Abstract][Full Text] [Related]
8. CLDN18.2 BiTE Engages Effector and Regulatory T Cells for Antitumor Immune Response in Preclinical Models of Pancreatic Cancer.
Xu Y; Fu J; Henderson M; Lee F; Jurcak N; Henn A; Wahl J; Shao Y; Wang J; Lyman M; Funes V; Espinoza B; Zhang R; Washington I; Chen SY; Zlomke H; Wang J; Niu N; Li P; Meng F; Burns W; Friedrich M; Stienen S; Bailis JM; Zheng L
Gastroenterology; 2023 Nov; 165(5):1219-1232. PubMed ID: 37507075
[TBL] [Abstract][Full Text] [Related]
9. Development and comparison of three
Hu G; Zhu W; Liu Y; Wang Y; Zhang Z; Zhu S; Duan W; Zhou P; Fu C; Li F; Huo L
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2634-2644. PubMed ID: 35347439
[TBL] [Abstract][Full Text] [Related]
10. Loss of Tight Junction Protein Claudin 18 Promotes Progressive Neoplasia Development in Mouse Stomach.
Hagen SJ; Ang LH; Zheng Y; Karahan SN; Wu J; Wang YE; Caron TJ; Gad AP; Muthupalani S; Fox JG
Gastroenterology; 2018 Dec; 155(6):1852-1867. PubMed ID: 30195448
[TBL] [Abstract][Full Text] [Related]
11. [
Zeng Z; Li L; Tao J; Liu J; Li H; Qian X; Yang Z; Zhu H
Eur J Nucl Med Mol Imaging; 2024 Apr; 51(5):1221-1232. PubMed ID: 38062170
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional regulation of claudin-18 via specific protein kinase C signaling pathways and modification of DNA methylation in human pancreatic cancer cells.
Ito T; Kojima T; Yamaguchi H; Kyuno D; Kimura Y; Imamura M; Takasawa A; Murata M; Tanaka S; Hirata K; Sawada N
J Cell Biochem; 2011 Jul; 112(7):1761-72. PubMed ID: 21381080
[TBL] [Abstract][Full Text] [Related]
13. Claudin-18.2 mediated interaction of gastric Cancer cells and Cancer-associated fibroblasts drives tumor progression.
Liu S; Zhang Z; Jiang L; Zhang M; Zhang C; Shen L
Cell Commun Signal; 2024 Jan; 22(1):27. PubMed ID: 38200591
[TBL] [Abstract][Full Text] [Related]
14. Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer.
Jia K; Chen Y; Sun Y; Hu Y; Jiao L; Ma J; Yuan J; Qi C; Li Y; Gong J; Gao J; Zhang X; Li J; Zhang C; Shen L
BMC Med; 2022 Jul; 20(1):223. PubMed ID: 35811317
[TBL] [Abstract][Full Text] [Related]
15. Colitis-associated colorectal adenocarcinomas frequently express claudin 18 isoform 2: implications for claudin 18.2 monoclonal antibody therapy.
Iwaya M; Hayashi H; Nakajima T; Matsuda K; Kinugawa Y; Tobe Y; Tateishi Y; Iwaya Y; Uehara T; Ota H
Histopathology; 2021 Aug; 79(2):227-237. PubMed ID: 33590909
[TBL] [Abstract][Full Text] [Related]
16. Claudin-18 is an early-stage marker of pancreatic carcinogenesis.
Tanaka M; Shibahara J; Fukushima N; Shinozaki A; Umeda M; Ishikawa S; Kokudo N; Fukayama M
J Histochem Cytochem; 2011 Oct; 59(10):942-52. PubMed ID: 21832145
[TBL] [Abstract][Full Text] [Related]
17. Safety and Pharmacokinetic Assessment of the FIC CLDN18.2/4-1BB Bispecific Antibody in Rhesus Monkeys.
Wang J; Dong T; Gong X; Li D; Sun J; Luo Y; Wu H
Int J Toxicol; 2024; 43(3):291-300. PubMed ID: 38115178
[TBL] [Abstract][Full Text] [Related]
18. Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody-Drug Conjugate for Treatment of CLDN18.2-Positive Cancers.
O'Brien NA; McDermott MSJ; Zhang J; Gong KW; Lu M; Hoffstrom B; Luo T; Ayala R; Chau K; Liang M; Madrid AM; Donahue TR; Glaspy JA; Presta L; Slamon DJ
Mol Cancer Ther; 2023 Dec; 22(12):1365-1375. PubMed ID: 37788341
[TBL] [Abstract][Full Text] [Related]
19. ZL-1211 Exhibits Robust Antitumor Activity by Enhancing ADCC and Activating NK Cell-mediated Inflammation in CLDN18.2-High and -Low Expressing Gastric Cancer Models.
Konno H; Lin T; Wu R; Dai X; Li S; Wang G; Chen M; Li W; Wang L; Sun BC; Luo Z; Huang T; Chen Y; Zhang J; Ye Q; Bellovin D; Wan B; Kang L; Szeto C; Hsu K; Kabbarah O
Cancer Res Commun; 2022 Sep; 2(9):937-950. PubMed ID: 36922936
[TBL] [Abstract][Full Text] [Related]
20. Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody.
Bähr-Mahmud H; Ellinghaus U; Stadler CR; Fischer L; Lindemann C; Chaturvedi A; Diekmann J; Wöll S; Biermann I; Hebich B; Scharf C; Siefke M; Roth AS; Rao M; Brettschneider K; Ewen EM; Şahin U; Türeci Ö
Oncoimmunology; 2023; 12(1):2255041. PubMed ID: 37860278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
